MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte operating margin

Operating margin is operating income as a percentage of revenue.

MaxCyte's operating margin for the twelve months ending Sep 30, 2026 was -98.0%. For fiscal 2025 it was -157.1%, against -132.5% the year before. The highest annual figure on record is -42.3% in fiscal 2020.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-157.1%	−24.6
FY2024	Dec 31, 2024	-132.5%	−15.6
FY2023	Dec 31, 2023	-117.0%	−55.2
FY2022	Dec 31, 2022	-61.8%	−8.2
FY2021	Dec 31, 2021	-53.7%	−11.4
FY2020	Dec 31, 2020	-42.3%	+15.2
FY2019	Dec 31, 2019	-57.4%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-59.5%	+147.7
Q2 FY2026	Jun 30, 2026	-140.7%	+26.5
Q1 FY2026	Mar 31, 2026	-64.1%	+54.2
Q4 FY2025	Dec 31, 2025	-153.8%	−5.4
Q3 FY2025	Sep 30, 2025	-207.2%	−35.1
Q2 FY2025	Jun 30, 2025	-167.2%	−52.5
Q1 FY2025	Mar 31, 2025	-118.3%	−10.1
Q4 FY2024	Dec 31, 2024	-148.4%	−96.7
Q3 FY2024	Sep 30, 2024	-172.1%	+2.2
Q2 FY2024	Jun 30, 2024	-114.8%	+29.8
Q1 FY2024	Mar 31, 2024	-108.2%	+45.4
Q4 FY2023	Dec 31, 2023	-51.7%	+2.7
Q3 FY2023	Sep 30, 2023	-174.3%	−101.8
Q2 FY2023	Jun 30, 2023	-144.6%	−53.6
Q1 FY2023	Mar 31, 2023	-153.7%	−117.8
Q4 FY2022	Dec 31, 2022	-54.3%	−5.5
Q3 FY2022	Sep 30, 2022	-72.5%	−48.4
Q2 FY2022	Jun 30, 2022	-91.0%	−28.8
Q1 FY2022	Mar 31, 2022	-35.9%	+62.2
Q4 FY2021	Dec 31, 2021	-48.8%	−20.8
Q3 FY2021	Sep 30, 2021	-24.1%	+17.9
Q2 FY2021	Jun 30, 2021	-62.1%	−6.9
Q1 FY2021	Mar 31, 2021	-98.1%	–
Q4 FY2020	Dec 31, 2020	-28.0%	–
Q3 FY2020	Sep 30, 2020	-42.0%	–
Q2 FY2020	Jun 30, 2020	-55.2%	–